Drugs / ZFN-603
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02800369 | Dec 2016 → Jun 2017 | human papilloma virus infection | Huazhong University of Science and Technology | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZFN-603 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02800369 ↗ |
| Action | Inhibit | “ZFN-mediated disruption of HPV16 and HPV18 E7 DNA directly decreased the expression of E7” NCT02800369 ↗ |
| Route | Other | “Subjects will receive suppository with ZFN-603 or ZFN-758” NCT02800369 ↗ |